Crohn's Disease Diagnostics and Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Crohn's Disease Diagnostics and Therapeutics Market Analysis
The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.
With the rise in COVID-19, the prevalence of other related complications also increased. According to a report by the SECURE-IBD database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus activated innate and adaptive immune responses upon entering the gastrointestinal tract. The study shows IBD patients' inflammatory reactions may cause intestinal damage. Also, a research article published in the Journal of Crohn and Colitis in March 2020 showed that IBD patients undertaking immune suppressors are associated with a greater risk of infections, even though there is no evidence to suggest that COVID-19 affects IBD patients more commonly than the general population. According to a review article in the World Journal of Gastroenterology in October 2020, it was comprehended that many COVID-19 patients were found to develop gastrointestinal complaints. Thus, there is an increasing demand for the Crohn's disease diagnostics and therapeutics market to manage further complications that could develop due to COVID-19.
The increasing occurrence of Crohn's disease is the primary driver predicted to boost the growth of the market. According to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD is around 7 million worldwide. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney, and liver diseases are higher in IBD patients than in non-IBD patients. In the older population (66 years and above), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30-day readmissions, and more extended hospital stays. Studies on the treatment of IBD for the prevention of such instances are a great boost to the development of the market during the forecast period.
The increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies to develop novel treatment options, is expected to provide the market studied with high growth potential.
Crohn's Disease Diagnostics and Therapeutics Market Trends
This section covers the major market trends shaping the Crohns Disease Diagnostic & Therapeutic Market according to our research experts:
The Anti-inflammatory Agents Segment is Expected to Witness Significant Growth During the Forecast Period
Anti-inflammatory agents have continued to lead as the largest sub-segment under the market's therapeutics segment due to their higher efficacy than immunosuppressants and analgesics. A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for Crohn's disease.
Additionally, the increasing investments, clinical trials, and key player activities are expected to contribute to the growth of the segment studied. For instance, in September 2022, rise therapeutics LLC received funding from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institute of Health to support proof-of-concept clinical testing of the therapeutic candidate, R-3750. It is an anti-inflammatory drug for the treatment of inflammatory bowel disease.
Similarly, in July 2021, Cerecord had positive initial phase 1 b results for CERC-002 in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments. Thus the abovementioned factors are expected to drive the growth of the segment studied during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market due to the increasing prevalence of the disease in the region. The increasing adoption of innovative medicines is expected to drive the demand for the Crohn's disease diagnostics therapeutics market in the North American region. An increase in research and development in clinical-stage companies in novel treatments for the disease is predicted to boost the growth of the Crohn's disease diagnostics therapeutics market in the region. In a study published in the Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States.
In this region, urbanization is a potential factor contributing to the increasing prevalence of Crohn's disease. The incidence of Crohn's disease has been attributed to the 'westernization' of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals. Also, the growth strategies of market players, such as partnerships, are expected to contribute to the growth of the market in this region. For instance, in January 2022, LifeArc partnered with the US-based Crohn's and Colitis Foundation to develop a prognostic for Crohn's disease in children. Thus the abovementioned factors are expected to drive the growth of the market in this region during the forecast period.
Crohn's Disease Diagnostics and Therapeutics Industry Overview
The Crohn's disease diagnostics and therapeutics market has growth opportunities in developing and developed nations. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some major market players include Pfizer Inc., Janssen Biotech Inc., GeneTech, Celgene Corporation, AbbVie Inc., and others.
Crohn's Disease Diagnostics and Therapeutics Market Leaders
-
Abbvie Inc.
-
Celgene Corporation
-
GeneTech
-
Janssen Biotech Inc.
-
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order
Crohn's Disease Diagnostics and Therapeutics Market News
- April 2022: Microbiotica received project funding from the Crohn's and Colitis Foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
- April 2022: Engitix collaborated with Takeda to expand an existing agreement to include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn's disease.
Crohn's Disease Diagnostics and Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
- 4.2.2 Demand for Prompt Diagnosis
- 4.2.3 Affected Population Increasing with Time
-
4.3 Market Restraints
- 4.3.1 No Specific Treatment or Drug Available in the Market
- 4.3.2 Lack of Awareness Among People and Symptom Similarity with Other Gastrointestinal Diseases
- 4.3.3 Lack of Cost-effective Treatment
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Diagnostics
- 5.1.1 Blood Test
- 5.1.2 Fecal Test
- 5.1.3 Colonoscopy
- 5.1.4 Flexible Sigmoidoscopy
- 5.1.5 Computerised Tomography
- 5.1.6 Magnetic Resonance Imaging
- 5.1.7 Other Diagnostic Tests
-
5.2 By Treatment
- 5.2.1 Medication
- 5.2.1.1 Anti-inflammatory Agents
- 5.2.1.2 Immunosuppressants
- 5.2.1.3 Analgesics and Antipyretics
- 5.2.1.4 Other Medications
- 5.2.2 Surgery
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbvie Inc.
- 6.1.2 Celgene Corporation
- 6.1.3 Genetech
- 6.1.4 Johnson & Johnson
- 6.1.5 Pfizer Inc.
- 6.1.6 Prometheus Laboratories Inc. (Nestle)
- 6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
- 6.1.8 Takeda's Pharmaceutical Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCrohn's Disease Diagnostics and Therapeutics Industry Segmentation
Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from the mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors in genetically predisposed individuals.
The Crohn's disease diagnostics and therapeutics market is segmented by diagnostics (blood test, fecal test, colonoscopy, flexible sigmoidoscopy, computerized tomography, magnetic resonance imaging, capsule endoscopy, other diagnostic tests), treatment (medication (anti-inflammatory agents, immunosuppressants, analgesics and antipyretics, other medications), surgery), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value in USD million for the above segments.
| By Diagnostics | Blood Test | |
| Fecal Test | ||
| Colonoscopy | ||
| Flexible Sigmoidoscopy | ||
| Computerised Tomography | ||
| Magnetic Resonance Imaging | ||
| Other Diagnostic Tests | ||
| By Treatment | Medication | Anti-inflammatory Agents |
| Immunosuppressants | ||
| Analgesics and Antipyretics | ||
| Other Medications | ||
| By Treatment | Surgery | |
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Crohn's Disease Diagnostics and Therapeutics Market Research FAQs
What is the current Crohn's Disease Diagnostic and Therapeutic Market size?
The Crohn's Disease Diagnostic and Therapeutic Market is projected to register a CAGR of 3.10% during the forecast period (2024-2029)
Who are the key players in Crohn's Disease Diagnostic and Therapeutic Market?
Abbvie Inc., Celgene Corporation, GeneTech, Janssen Biotech Inc. and Pfizer Inc are the major companies operating in the Crohn's Disease Diagnostic and Therapeutic Market.
Which is the fastest growing region in Crohn's Disease Diagnostic and Therapeutic Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Crohn's Disease Diagnostic and Therapeutic Market?
In 2024, the North America accounts for the largest market share in Crohn's Disease Diagnostic and Therapeutic Market.
What years does this Crohn's Disease Diagnostic and Therapeutic Market cover?
The report covers the Crohn's Disease Diagnostic and Therapeutic Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Crohn's Disease Diagnostic and Therapeutic Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Road Safety Industry Report
Statistics for the 2024 Road Safety market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Road Safety analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
